Dimerix Limited (ASX:DXB)


right-arrow Created with Sketch. -0.01 (-4.17%)
MCAP $77.00M
Last trade 11.42am 06/12/2021 20mins delayed

Latest Announcements

23/11/2021DXBDimerix Limited
25/10/2021 Price SensitivePSDXBDimerix Limited
21/10/2021 Price SensitivePSDXBDimerix Limited
15/10/2021 Price SensitivePSDXBDimerix Limited
07/10/2021DXBDimerix Limited
05/10/2021DXBDimerix Limited
05/10/2021DXBDimerix Limited
05/10/2021DXBDimerix Limited

Company Overview

Dimerix Limited is an Australia-based biopharmaceutical company. The Company is engaged in the development of new therapies in areas with unmet medical need. The Company is developing four product indications: Focal Segmental Glomerulosclerosis (FSGS), respiratory complications associated with COVID-19, diabetic kidney disease, and DMX-700 for Chronic Obstructive Pulmonary Disease (COPD), as well as the its Receptor-HIT assay technology. The Company’s pipeline products include DMX-200, DMX-700 and DMX-XXX. DMX-200, which is developed for FSGS, COVID-19 pneumonia patient in ICU and respiratory complications in COVID-19 patients is under Phase III clinical trial. DMX-200, which is developed for diabetic kidney disease is under Phase II clinical trial. DMX-700, which is developed for COPD is under Phase I clinical trial. DMX-XXX is under Phase I clinical trial.

DXB in the news

Dimerix (DXB) is granted Australian ethics and regulatory approval for its Phase…
Dimerix (DXB) enters an agreement with the NHMRC Clinical Trials Centre at…
Clinical-stage biopharmaceutical company Dimerix (DXB) successfully completes its share purchase plan (SPP)The…
The Indian regulatory agency recommends Dimerix’s (DXB) DMX-200 clinical study in COVID-19…

Search Previous Announcements